Epacria Capital Partners LLC Purchases 4,026 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Epacria Capital Partners LLC increased its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 26.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,190 shares of the biopharmaceutical company’s stock after acquiring an additional 4,026 shares during the period. Epacria Capital Partners LLC’s holdings in Royalty Pharma were worth $543,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of RPRX. Versant Capital Management Inc increased its position in Royalty Pharma by 5,215.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,043 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Royalty Pharma in the second quarter valued at approximately $32,000. Blue Trust Inc. increased its holdings in shares of Royalty Pharma by 362.7% in the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 943 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 655 shares during the last quarter. Finally, Transamerica Financial Advisors Inc. lifted its holdings in Royalty Pharma by 99.9% during the 3rd quarter. Transamerica Financial Advisors Inc. now owns 3,459 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,729 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RPRX shares. The Goldman Sachs Group lifted their target price on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Citigroup lowered their price objective on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Finally, StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.67.

Royalty Pharma Trading Up 1.2 %

NASDAQ RPRX opened at $26.60 on Friday. Royalty Pharma plc has a 12 month low of $25.10 and a 12 month high of $31.66. The stock has a 50-day simple moving average of $27.16 and a 200 day simple moving average of $27.34. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $15.67 billion, a PE ratio of 13.78, a P/E/G ratio of 4.67 and a beta of 0.47.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.16%. Royalty Pharma’s dividend payout ratio (DPR) is presently 43.52%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.